P61 Bone Mineral Density Loss in Tenofovir Treated Chronic Hepatitis B Virus (HBV) Patients Is a Consequence of Vitamin D Deficiency and Not Tenofovir Therapy

Gut - United Kingdom
doi 10.1136/gutjnl-2011-300857a.61
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Hepatitis B Virus (HBV) Variants in Untreated and Tenofovir Treated Chronic Hepatitis B (CHB) Patients During Pregnancy and Post-Partum Follow-Up

PLoS ONE
Multidisciplinary
2015English

Letter: Distinct Hepatitis B Virus Relapse Rates After Discontinuing Tenofovir and Entecavir Therapy in Chronic Hepatitis B Patients

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Decreased Neonatal Hepatitis B Virus (HBV) Viremia by Maternal Tenofovir Treatment Predicts Reduced Chronic HBV Infection in Children Born to Highly Viremic Mothers

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Tenofovir and Its Potential in the Treatment of Hepatitis B Virus

Therapeutics and Clinical Risk Management
2009English

Renal Safety of Tenofovir and/or Entecavir in Patients With Chronic HBV Monoinfection

Therapeutics and Clinical Risk Management
2017English

Renal Concerns in the Treatment of Chronic Hepatitis B With Tenofovir

Journal of Renal and Hepatic Disorders
2017English

Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection: Rationale and Clinical Trial Evidence

Therapeutic Advances in Gastroenterology
Gastroenterology
2018English

Tenofovir (TDF) Has Stronger Antiviral Effect Than Adefovir (ADV) Against Lamivudine (LAM)-resistant Hepatitis B Virus (HBV)

Hepatology International
Hepatology
2008English

Tenofovir Plus Entecavir Combination Therapy for Chronic Hepatitis B With Nucleos(t)ide Analogue Failure

The European Research Journal
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy